September 2011 - Equations that estimate a patient's kidney function work as well as direct, invasive measurements, according to a study appearing in an upcoming issue of the Journal of the American Society Nephrology (JASN). This means that many patients with chronic kidney disease (CKD) do not need to undergo the painful and cumbersome procedures that are performed to monitor kidneys' health.
Measuring CKD patients' kidney function can help physicians anticipate complications and provide optimal treatments. Most measures focus on patients' glomerular filtration rate (GFR), or the rate that the kidneys filter wastes from the urine. Clinicians have traditionally assumed that directly testing GFR by injecting a tracer agent such as iothalamate provides a better measure of kidney function than calculating GFR indirectly with an equation. However, iothalamate GFR (iGFR) is more cumbersome and invasive than equation-estimated GFR (eGFR). Specifically, iGFR involves injecting a (sometimes radioactive) agent, taking multiple blood samples, and doing timed urine collections, while eGFR involves one simple blood test.
To compare the tests, Chi-yuan Hsu, MD (University of California, San Francisco) and his colleagues looked to see which is more strongly and consistently linked with common CKD complications in 1,214 CKD patients who participated in the Chronic Renal Insufficiency Cohort (CRIC) study, which includes the largest ever group of CKD patients assembled and is sponsored by the National Institute of Diabetes and Digestive and Kidney Diseases.
The investigators found that eGFR linked just as tightly to CKD complications as iGFR. These results refute the conventional view that iGFR is in fact the gold standard measure of kidney function. "For many purposes and for many patients, relying on equations to estimate GFR alone may be sufficient, and patients can avoid undergoing more invasive assays to directly measure GFR," said Dr. Hsu.
Approximately 60 million people globally have CKD. Early detection and treatment can prevent kidney failure, but individuals with the disease often do not experience symptoms until later stages.
Study co-authors include Kathleen Propert, PhD, Dawei Xie, PhD, Valerie Teal, Raymond Townsend, MD, Harold Feldman, MD (University of Pennsylvania); Lee Hamm, MD, Jiang He, MD, PhD (Tulane University); Edgar Miller, MD (Johns Hopkins University); Akinlolu Ojo, MD, PhD, Jillian Wilson (University of Michigan, Ann Arbor); Michael Shlipak, MD (University of California, San Francisco); and Matthew Weir, MD (University of Maryland). The authors reported no financial disclosures.
The article, entitled "Is iGFR Really Better than eGFR? Analyzing Associations with Common Co-morbid Conditions," will appear online
Source: American Society of Nephrology
